USFDA completes Ghaziabad plant inspection, no observations issued: Unichem
New Delhi: Drug firm Unichem Laboratories said it has not received any observations from the US health regulator after completion of inspection of its Ghaziabad facility in Uttar Pradesh.
The company's formulation manufacturing facility at Ghaziabad was inspected by the United States Food and Drug Administration (USFDA) from April 16, 2018, to April 20, 2018, Unichem Laboratories said in a BSE filing.
The inspection concluded with zero observations, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd